Jinxin Fertility: Accretive but Slightly Controversial Acquisition of Jinxin WCH
We attended management call to understand its acquisition of Jinxin Woman and Children Hospital. Though the deal dilutes the core IVF business it...
409 Views
Hygeia Healthcare (6078.HK) 2021H1 - Efficient Expansion and Management Support the Positive Outlook
This article analyzed Hygeia in terms of its 2021/1H financial result, the management mode, talent cultivation, new policy on professional title...
365 Views
Jinxin Fertility 1H2021: A Clear Picture of the Long Term Potential
Jinxin Fertility's conference call following the 1H2021 results provided a clearer picture of its execution capability and long term growth drivers...
382 Views
Jinxin Fertility: Signs of Policy Tailwind and Valuation Dislocation
We think there's a dislocation of Jinxin Fertilities' share following the sell-off of Chinese stocks due to the policy targeting education...
319 Views
Wuxi Biologics Placement - Similar Deal Will Yield Similar Results
Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 1.8% of Wuxi Biologics (2269 HK). This is the company's 15th placement...
596 Views